

## Company Overview

Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's intimate health company based in Englewood, Colorado. The company is focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven, cryogen-cooled, monopolar radiofrequency (CMRF) energy to uniformly deliver deep- penetrating volumetric heat while gently cooling surface tissue to generate robust neocollagenesis in a single in-office session.

In the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Consistent with these approvals, in the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the U.S. Food and Drug Administration (FDA) in March of 2018. If successful, this trial could support a marketing application for a new U.S. commercial indication.

Viveve has initiated LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and has submitted an IDE to the FDA for LIBERATE-U.S. The results of these two studies, if successful, could support marketing applications in the U.S, and additional countries around the world for this new commercial indication.

## Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference

Sep 25 2018, 8:28 AM EDT

## Viveve Appoints Two New Independent Board Members

Sep 13 2018, 8:28 AM EDT

## Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence

Sep 11 2018, 8:28 AM EDT

## Stock Overview

Symbol	VIVE
Exchange	Nasdaq
Shares OS	31,488,506
Market Cap	\$88.48M
Last Price	\$2.81
52-Week	\$1.60 - \$5.99

09/25/2018 04:00 PM EDT

## Investor Relations

Stern Investor Relations, Inc.  
1270 Avenue of the Americas  
Suite 408  
New York, NY 10020  
T: (212) 362-1200  
[Sarah@sternir.com](mailto:Sarah@sternir.com)

## Management Team

### Scott Durbin

Chief Executive Officer and Director

### James Atkinson

Chief Business Officer and President

### Suzon Lommel

Senior Vice President of Regulatory and Quality Affairs

### Jim Maffezzoli

Senior Vice President of Global Marketing

### Debbie Wilkerson, Ph.D.

Vice President of Clinical and Medical Affairs

### Jim Robbins

Vice President of Finance and Administration, Principal Accounting Officer

### Marty Kerber

Vice President of Operations

### Sean Shapiro

Vice President of U.S. Sales

### Lori McMillan

Vice President of Human Resources

---

## Viveve Medical, Inc.

345 Inverness Drive South  
Building B, Suite 250  
Englewood, CO 80112

---

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.